Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia in Japan
The purpose of this study is to evaluate effectiveness of Dasatinib as the first line therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase in Japan.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive|Myelogenous Leukemia, Chronic, Chronic Phase
Rate of complete molecular response (CMR) after treatment with dasatinib, The rate(%) of patients who achieve complete molecular response (CMR) by 18 months after the dasatinib therapy will be measured to evaluate the efficiency of dasatinib., by 18 months
complete molecular response (CMR), by 3,6,12,24, 36 months|Major Molecular Response(MMR), by 3,6,12,18,24,36 months|Complete Cytogenetic Response(CCyR), by 6,12 months|Expansions rate of large granular lymphocyte, by 12 months|Progression free survival, at 36 months|Number of Participants with Adverse Events as a Measure of Safety and Tolerability, by 36 months
The purpose of this study is to evaluate effectiveness of Dasatinib as the first line therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase in Japan.